Drimva

GSK

Director, Quantitative Systems Pharmacology

$188K–$314K

USA - Pennsylvania - Upper Providence +4 · Hybrid (Remote & On-site) · Director · Full-time · Posted Oct 12, 2026

Location
USA - Pennsylvania - Upper Providence
GSK HQ
UK - Hertfordshire - Stevenage
Waltham
Durham Blackwell Street
Experience
Minimum 7 years; experience in mechanistic mathematical modeling, inverse problem modeling and simulation, and/or scientific machine learning methodologies.
Education
PhD, MD, or PharmD.

About the job

Leads quantitative systems pharmacology modeling and strategy to support drug discovery and development in GSK’s Respiratory, Immunology and Inflammation portfolio.

What you'll do

  • Build and guide mechanistic QSP and QST models and simulations to understand disease, drug action, and trial design.
  • Define and coordinate QSP/QST and clinical pharmacology development strategies, integrating evidence across disease programs.
  • Collaborate with cross-functional and external experts, advise leadership, and communicate research through scientific publications.

What they ask for

  • PhD, MD, or PharmD, with experience in mechanistic modelling and simulation and systems biology applied to pharmaceutical R&D.
  • At least 7 years in mechanistic mathematical modeling, inverse problem modeling and simulation, and/or scientific machine learning applied to preclinical or clinical drug-development questions.
  • Experience working with senior stakeholders in a cross-functional environment.
  • Track record implementing Model-Informed Drug Discovery and Development (MIDD) approaches.

Nice to have

  • Prior experience in Hepatology, Respiratory and/or Cardiometabolic diseases.
  • Ability to collaborate effectively, communicate, exercise sound judgment, and adapt priorities in complex situations.

Pay

$188,100 to $313,500 USD annual base salary

Tools

QSP, QST, scientific ML, AIML, inverse-problem modelling, Model-Informed Drug Discovery and Development (MIDD)

AI focus

Use scientific machine learning and AIML alongside mechanistic modeling to improve model development and support drug-development decisions.

Model-written summary · the original posting is authoritative

First seen Oct 28, 2026 · Last verified Nov 5, 2026 (UTC)